For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results. The company ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

Dave Fredrickson of AstraZeneca highlighted that the approval of Calquence provides nearly one and a half years of additional disease progression-free time for patients, affirming its potential as ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...